Coronary Artery Disease Clinical Trial
— ACCTHEROMAOfficial title:
Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease.
Verified date | February 2017 |
Source | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In human purified platelets, only thrombin, and not the other platelet agonists, leads to a
transient activation of the protein kinase activated by AMP (AMPK) and to phosphorylation of
its "bona fide" substrate, ACC on its Ser79. ACC phosphorylation (P-ACC) can be an
interesting marker of thrombin action on platelets. Indeed platelet and coagulation
interplay, though undoubtedly present in atherosclerosis and atherothrombosis, remains
difficult to assess. Our group showed that atherosclerotic mice (SRBI/Apolipoprotein E
knock-out) had higher platelet P-ACC compared to corresponding control mice (C57BL6). In
agreement with these data, preliminary results showed increased platelet P-ACC in a small
cohort of patients admitted for coronary angiogram, with demonstrated coronary artery
disease (CAD).
In the light of our preliminary results, we sought to analyze platelet P-ACC in a large
prospective clinical trial (ACCTHEROMA) in patients admitted for coronary angiogram. The aim
of the study is to compare platelet P-ACC in platelets of patients with CAD and more
particularly in unstable CAD patients to non-CAD patients. This study could potentially
identify patients at high risk of future ischemic cardiovascular events, because of a higher
level of thrombin generation.
Status | Completed |
Enrollment | 188 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed informed consent - Planned angiography within the next 3 days, whatever the indication. Exclusion Criteria: - Not able to sign informed consent - Patients on anticoagulation therapy (oral or parenteral) including heparins, fondaparinux, vitamin K antagonist, novel oral anticoagulants, for any reasons. - Active neoplasia - Active inflammatory disease - Patients with life expectancy lower than 3 years - Haemophilia and other coagulopathy - Abnormal platelet count - Heart transplanted patients - Active hepatitis B or C or HIV patients - Any contra-indication for coronary angiography. |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Saint Luc | Brussels |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Belgium,
Onselaer MB, Oury C, Hunter RW, Eeckhoudt S, Barile N, Lecut C, Morel N, Viollet B, Jacquet LM, Bertrand L, Sakamoto K, Vanoverschelde JL, Beauloye C, Horman S. The Ca(2+) /calmodulin-dependent kinase kinase ß-AMP-activated protein kinase-a1 pathway regul — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | an increase in platelet ACC phosphorylation state in patients with coronary artery disease | 2 years | ||
Secondary | a correlation between thrombin generation markers and platelet P-ACC in overall population. | 2 years | ||
Secondary | platelet ACC phosphorylation state according clinical severity of CAD (stable versus unstable patients) | 2 years | ||
Secondary | the role of platelet P-ACC in predicting the risk of the patient for future cardiovascular events (death, myocardial infarction, stroke) | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |